CervicalCheck Steering Committee

Weekly report to the Minister

23 November 2018

1. Update on support package

The provision of supports to women and families is continuing and the HSE reports that Liaison Officers are working actively to better coordinate supports and to assist in future planning for the service. It is hoped that this work will be concluded in the coming weeks.

The Government decision of 11 May provided that where women had been prescribed a medicine by their treating clinician, any out-of-pocket costs would be met. Arrangements are in place to reimburse, on receipt of claims, a range of costs that the women and their families incur from 11 May including travel costs, childcare costs and medical appointment costs among others. Reimbursement of retrospective costs is taking place, and an automatic review system is in place to simplify and streamline the process to ensure prompt payment of all items covered by the Government decision. To date, €1.02m has been reimbursed in respect of various health and social care costs, approximately €818,000 of which relates to retrospective payments. There will also be additional costs associated with the medical cards that have been issued and the meeting of certain drug costs.

A note in relation to financial support for patient advocates was submitted to the Minister for consideration in recent weeks.

2. Release of records

The HSE remains focused on responding to all requests for records as soon as possible. To aid this process external legal advisors are liaising with women and their solicitors on the release of slides. The protocol in place ensures the integrity and traceability of slides being transferred; solicitors are required to provide specific information about their chosen laboratory before slides can be released; this ensures the integrity of the slide is protected and all slides can be traced when they leave their current location. The HSE has reported that the average time to deliver slides to independent experts is 25 days.

Release of some slides has been delayed. Legal representatives for the HSE have contacted solicitors to check if they are encountering any delays and to address any issues. Arising from this exercise, a number of cases have been identified where the HSE have not been informed of the requestor's name and/or the designated lab expert to whom the slides are to be sent. As a result, the HSE are working with these solicitors to ensure that all required details are sent to the labs.

3. Independent Expert Panel Review

The protocol for the International Clinical Expert Review led by the Royal College of Obstetricians and Gynaecologists (RCOG) has been published on the Department of Health website.

Almost 1,600 letters have now issued providing information in relation to consent and the consent form for participation in the review, which is the total number of letters issuing directly to women affected. The remaining letters are all those issuing to next of kin of women who have, sadly, died.

Next of kin details are being provided by the relevant acute hospital. The Department will continue to engage with the HSE to ensure that validation is completed and remaining letters issue as expeditiously as possible.

Approximately 858 women have consented to take part in the review. Reminder letters have started issuing to those who have not yet responded and the last reminder letters will issue this week.

4. Validation exercise in relation to the 221 affected women

The HSE has advised it will soon commence a validation exercise on the data held on the 221 affected women. This is to ensure the National Screening Service has the most up to date information, which will be used to help with planning support needs for patients, for example.

5. Laboratory contracts

Heads of Agreement have been signed with the contracted labs to extend their contracts for cytology services pending the introduction of HPV testing as the primary screening test. This allows for the continuation of the service without interruption. The HSE is now in the process of concluding final contracts and operating arrangements, with efforts to secure additional laboratory capacity to help address the backlog of smears being part of these negotiations.

6. Introduction of HPV as the primary method of testing

The introduction of HPV testing as the primary screening mechanism for CervicalCheck, with cytology as a reflex test, will involve a reconfiguration of the laboratory work involved. Detailed capacity planning is ongoing and introduction will be subject to a tendering process for work carried out outside the public sector.

The Clinical Advisory Group established to advise on the project has made a decision in relation to the choice of HPV assay, required before tender documents can be finalised, as well as the final age range and intervals and genotyping. Dr Marc Arbyn, who was a member of the HIQA HTA panel, is also providing support and expertise to this Group. HSE officials have advised that all necessary clinical decisions which are required for drafting of procurement documents have now been made and procurement market analysis is progressing.

The notice of engagement to the market went live on etenders last week, with a market engagement seminar scheduled for 27 November. Work is ongoing to finalise the laboratory strategy for the HPV test, taking account of options and the future proofing of the service. In tandem, work on development and testing of necessary ICT changes is underway and colposcopy capacity planning is being scoped out.

7. Smeartaking activity

Continuity of supply arrangements are in place with the existing laboratories to ensure the continued provision of cytology services until the introduction of the HPV testing regime. The increased demand has undoubtedly put immense pressure on lab capacity and the HSE has been working actively with the labs to manage this. The total number of additional GP consultations to date is now 95,881 with 836 consultations in the week ending 9 November. The issue of the backlog of smear tests remains a priority concern for the HSE. As outlined above, efforts to secure additional laboratory capacity to help address the backlog of smears form part of the finalisation of laboratory contract extensions.

8. Alternative resolution mechanisms

Judge Meenan's report on alternative mechanisms to avoid adversarial court proceedings for women and their families affected by CervicalCheck was approved by Government on 16 October. Consideration of Judge Meenan's report is ongoing.

9. Implementation of recommendations of the Scally Inquiry

The HSE working group which is addressing the recommendations of the First Report on information about screening for women has continued its work, and planning for the implementation of the 50 recommendations contained in the final report of the Scoping Inquiry has begun.

Work on the Implementation Plan for the recommendations of the CervicalCheck Scoping Inquiry is continuing, with the aim of finalising the Plan to allow for submission to Government within the three-month timeframe set out by Dr Scally. The plan was submitted to Dr Scally for his independent review on 23 November.

The next meeting of the CervicalCheck Steering Committee is scheduled for 29 November, with a further meeting to follow on 18 December.

Oversight and engagement with the HSE on modules of their work as follows:

- Management of supports to patients/families
- Provision of documents to patients
- Interface with RCOG Review
- Management of laboratory capacity issues
- Introduction of HPV Screening

Management of supports to patients/families	
Significant Issues	There are no exceptional items to report in relation to Community Supports.

Provision of documents to patients

Significant Issues

Current position, issues & challenges

The team remains focused on responding to all requests as soon as possible. External legal advisors are liaising with women and their solicitors on the release of slides. Solicitors are required to provide specific information about their chosen laboratory before slides can be released. This ensures the integrity of the slide is protected and all slides can be traced when they leave their current location. In some cases there have been delays with the laboratories due to operational pressures and we are ensuring that we continue to focus on reducing the time taken - the average time to deliver slides to the independent expert is 25 days.

In relation to access to slides: some concerns were expressed in relation to significant numbers of women not getting access to slides, as a result we contacted all solicitors to establish if there were indeed people waiting on slides. As a result we have identified a significant number of cases where the HSE have not been informed of the requestors name or/and their designated lab expert where the slides are to be sent to – as a result we are working with those solicitors to ensure that all required details are being sent to the labs.

Interface with RCOG Review	
Project Management	Project Manager in Place Assistant National Director (HSE) commenced working as the Programme Lead on the RCOG Review on Wednesday the 1 st of August. Project Manager (HSE) commenced working as the Project Manager on Wednesday the 1 st of August.
Project Governance	 Programme Governance Support Team holds daily meetings and teleconferences to progress deliverables, identify critical actions / timeframes, areas for escalation, and project RAIDS. Teleconference with RCOG and Dept. of Health to progress interagency logistics and communication, and discuss timeframes Next steps
	Continue weekly teleconference with Dept. of Health and Expert Review Panel

Project Plan

Workstream	Actions Progressed (w/e 16 th Nov)
Patient Support Services	 As of Friday 16th November: 1,531 invited to participate in Expert Panel Review, who are contactable and comprehended by the Review. 858 (56%) have consented to participate in the Review (an increase of 5 from previous week)
Information Services	 As volume of calls has decreased to avg. 1 per day, opening hours of call centre reduced from 7 to 5 days a week 9am – 6pm. To be revisited when more letters issue. As of Fri 9th Nov, there have been 112 calls to the information line (an increase of 6 from previous week). Detailed as follows:

	Total Calls to Information Line	112	
	Total Calls (general)	40	
	Total Calls (general)	72	
	Calls (clinical) resolved at initial contact	49	
	Calls (clinical) escalated to acute hospitals, following SOP	23	
	Calls (clinical) resolved by acute	23	
	hospitals		
Case Management System (CMS)	 Completed application to NCRI submitted for RCOG's access to relevant CMS updated to include new information provided by NSS/NCRI/GRO. Working to incorporate additional requirements for slides transfers who Engaging with CervicalCheck ICT to facilitate Expert Review Panel v required. 	are also involved in lega	
Laboratory Logistics	 SOP for transfer of slides sent to CervicalCheck Labs for review and agre Nov Updated list of women consenting to review provided to labs to commendation 		eceived by Fri 16 th
Communications	Follow up with Dept. of Health and RCOG regarding outstanding fe communications plan	edback on Stakeholder	engagement and
Acute & Community Services	 Weekly briefing sent to Acute Operations for onward circulation to releve Colposcopists through CervicalCheck Weekly teleconference with Acute Operations Progressing validation of Next of Kin details with Acute services as per agent Responses provided to individual clinicians who have contacted the Programme and the Expert Panel Review. 	greed SOP, where wome	n are deceased.
Current Position, Significant Issues	 Ascertaining Next of Kin details for deceased women through acute and expected as it requires review of medical records for this information. After consent letters issued, the RCOG Support Team was made aware t 		


within the scope of the Review. This issue was raised with NSS ICT and the Office of the CIO (Data Quality), which
provided the datasets used for undertaking the consent process, and they are investigating against NCRI data provided to
them. The RCOG Team is undertaking a continuous process of review and revalidation of data provided to date.

Next Steps

Workstream	Actions Planned (w/c 19 th Nov)
Patient Support Services	 Issue cohort of letters to Next of Kin where details validated by acute services. Follow up to ascertain outstanding Next of Kin contact details with primary care. Issue reminder letters to women Continue scanning and logging consent returns on Case Management System, as they are received. Continue regular engagement with Patient Liaison Officers and other stakeholders.
Information Services	 Continue follow-up on calls to information line and to dedicated email address for health professionals Employ regular quality checks to ensure capacity meets demand. Where required, identify and assign further additional clinical & administrative resources to the call centre in line with the project plan timelines.
Case Management System (CMS)	 As letters issue, continue to update CMS with validated data Progress design of CMS to be updated further in line with agreement on labs transport process.
Laboratory Logistics	 Follow up with labs where feedback on SOP is outstanding Commence transfer of slides from CervicalCheck laboratories to RCOG laboratory (Bristol, UK).
Communications	 Finalise SOP for the interagency management of public/non patient queries (i.e. press, FOIs, PQs, public representations) related to the RCOG review with feedback from DOH and Expert Review Panel. Manage feedback and queries from women/Next of Kin, clinicians, media and public as remaining cohorts of women of next of kin receive letters.

Acute & Community Services

Management o	f Laboratory Capacity Issues
Project	Project Manager in Place
Management	Project Team Composition
	Given the nature of the issues presenting, a working group was put in place to support the project manager. This group comprise HSE procurement, HSE Legal and the CervicalCheck Operations team. This group is focused on a) extension of lab contracts and b) managing the demand due to the out of cycle smear tests.
Project Plan	Since April any woman who is concerned can attend her GP for a free smear and this has resulted in a testing backlog in all three labs. These delays remain a priority concern for the HSE. Because of the skilled nature of cytology screening and the difficulty in recruiting trained staff, lab turnaround time issues can be slow to resolve. Laboratories are required to capture the smear on a slide within 6 weeks. This has been resolved with the laboratory so we do not foresee future issues. The lab working group continues to work closely with the three labs to understand and manage current capacity issues. Weekly reports are being provided and ongoing engagements to identify further actions to mitigate this risk.
	We are happy to say that we agreed continuity of supply arrangements with both existing cytology laboratories so that they continue to provide cytology services to CervicalCheck beyond the end date of the contract on Sunday 14 th October. We are now concluding final contracts and operating arrangements with both Quest and Medlab pathology over the coming weeks. We are also trying to secure additional laboratory capacity as part of these negotiations.
Uptake of	Out of cycle smears
Smear Tests	Total number of additional GP consultations to date is more than 95,000. The knock on effect of this has been 1) the estimated number of early repeat smear test to take place in the period of 1 st May to 31 st October is in the region of 48,088 2) a Global trend with respect to decreases in the availability of cytology staff has also exacerbated the ability of the contracted labs to increase their throughput through this



Project Management	Project Manager A Project Manager is in place. The expression of interests for the appointment of a Clinical Lead for the HPV primary screeni project, a lead cytopathologist and a lead colposcopist were unsuccessful. NSS are currently reviewing options. Project Team Composition	
	 Clinical Advisory Group: international expert Dr. Marc Arbyn is supporting this group. Dr Arbyn was a member of the HIQA HTA panel and is a leading expert on HPV primary screening in Europe Still awaiting Clinical lead, Colposcopy lead, Pathology lead. 	
Project Plan		
Workstream	Actions Progressed (w/e 16 th November 2018)	
Clinical	 Steering Group presented clinical work decisions made to date Assessment of feedback to proposed screening pathway and eligibility framework continues. 	
Procurement	 The Notice of engagement to the market went live on etenders last week, this seminar is scheduled to take place in the NSS on Tuesday 27th November. Pre-registration of participation is required. 	
ICT	 CSR development- Complete and application delivered to NSS for testing. All test resources are now in place and we have commenced Unit testing of the individual changes and testing of SSIS packages. Preparation for full system test has begun Colposcopy IT- Changes required agreed and estimate provided by 1 of the 2 vendors. (€30k approx.) Laboratory IT development awaiting decisions on laboratory configuration and procurement. New form has been made available to all practices in hardcopy and on the Programme website. The electronic copy has been delivered to Healthlink who are dealing with the accredited practice management system vendors. No delivery estimate available yet. 	

seminar is completed to understand the commercial interest.

Configuration options paper continued to be developed but work is limited until the market engagement

Lab Configuration

Communications	Communications lead identified for this project
Resources for HPs	 Team continue to work on 2 pieces: 1. Developing training materials & the e-learning modules 2. Guide for Primary Care which will be available in hardcopy and through the e-learning portal
Hospitals (Colposcopy)	 Colposcopy capacity planning and management of women referred to colposcopy continues to be scoped out. Hospital Group CEOs have officially been communicated to regarding this piece of work by ND Acute Operations
Current Position,	Current position, issues & challenges
Significant Issues	 Continuing efforts to secure contract extensions with existing labs is critical to enable the programme to proceed. Stabilisation of the current programme remains a huge issue. Current backlogs from the 2 private providers wil impact the transition to HPV primary screening. Absence of a fulltime Clinical Director for the programme is impacting a number of key activities. Decision required on the cervical screening pathway A Clinical Advisory Group has been set up to address these decisions. Failure to recruit a colposcopy or cytopathology lead for the program and project. There were no applicants. A letter of invite for a colposcopy lead will be re-issued to Dr Peter Boylan, Chair of the Institute for Gynaecologis and Obstetricians. Laboratory configuration strategy being reassessed by requirements to stabilise current programme. Market engagement seminar, originally planned to be completed in October to assess private lab interest in tendering for HPV primary screening, will now take place in November. Communications resources (external & internal) have been identified and work now will commence on a communications plan for the transition to HPV primary screening

Immediate Activities

Workstream	Actions Planned
Clinical	Circulate scope of work and arrange series of meetings with colposcopy leads in November.
Procurement	 Finalise contract details with labs following agreement to continue. Pre-tender Market engagement seminar on the 27th in the NSS. Finalise slide deck, logistics and Comms plan for market engagement seminar.
ICT	 Testing of changes to Cervical Screening Register. (February 2019) Labs ICT development - Awaiting nomination of labs to be contacted Colposcopy IT - Awaiting feedback from the second vendor. Funding approval to be sought once we get the second estimate and a development and testing schedule can be agreed.
Lab Configuration	Laboratory configuration strategy to be finalised looking at the options and future proofing services.
Communications	 Workshop on the detail of the Comms plan to take place on 21st Nov with the PMO. Finalise stakeholder mapping exercise with workstream leads. Arrange a workshop with CervicalCheck staff, National Comms, service user rep & smear takers to agree an approach to develop a Comms plan.
Resources for HPs	 Scope out work on mandatory training for the HPV roll out as indicated by Dr. Scally . Mandatory training to be discussed at QS &RM meeting and next QA Committee (23rd Nov) Progress materials development and the appointment of the elearning technologist.
Hospitals (Colposcopy)	 Complete capacity planning exercise and schedule meetings with lead colposcopists Secure hospital commitments for 2019. Identify colposcopy lead for HPV project.
Jpdate Action	Update Action 04/28 Update on the possibility of appointing a clinical lead for the move to HPV testing. Update on 02/10/18 -The expression of interest was extended to the 10 th Oct.

Update 19/09/18 NRS are finalising the contract with the successful candidate for the post of clinical director.